Sign in
4

Changes in Ownership

Edgewise Therapeutics, Inc. Filed Acc 0001562180-24-008599

Chief Development Officer sold 29,709 shares at an average $29.69 ($881,915)

  • Chief Development Officer acquired 29,709 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Semigran Marc · Chief Development Officer

Table I: Non-derivative

3 lines
Date Transaction Shares Price Value Owned after D/I
2024-12-24 Exercise or conversion : show line 1 in the form 10b5-1 +29,709 $8.94 $265,598 36,425 D
2024-12-24 Sale : show line 2 in the form 10b5-1 −27,980 $29.66 $829,906 8,445 D
2024-12-24 Sale : show line 3 in the form 10b5-1 −1,729 $30.08 $52,009 6,716 D
Open-market sales · 29,709 sh · avg $29.69 · $881,915

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2024-12-24 Exercise or conversion : show line 4 in the form 10b5-1 Stock Option (Right to Buy) −29,709 270,291 D
Loading xslF345X05/primarydocument.xml…